Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.43 |
| ▸ | NCF1 | P14598 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14900003 | 1.00 | ALDH1A1 (0.47) | ALDH1A1GNAI3GNAO1GNAI1SLC18A3 | |
| SCHEMBL19343090 | 1.00 | ALDH1A1 (0.47) | ALDH1A1GNAI3GNAO1GNAI1SLC18A3 | |
| SCHEMBL20047011 | 0.97 | ALDH1A1 (0.50) | ALDH1A1GNAI3GNAO1GNAI1SLC18A3 | |
| SCHEMBL19343088 | 0.97 | ALDH1A1 (0.50) | ALDH1A1GNAI3GNAO1GNAI1SLC18A3 | |
| SCHEMBL23713738 | 0.95 | ALDH1A1 (0.42) | ALDH1A1GNAI3GNAO1GNAI1SLC18A3 | |
| SCHEMBL19343095 | 0.91 | GNAI3 (0.45) | ALDH1A1GNAI3GNAO1GNAI1SLC18A3 | |
| SCHEMBL19226519 | 0.91 | GNAI3 (0.45) | ALDH1A1GNAI3GNAO1GNAI1SLC18A3 | |
| SCHEMBL19673940 | 0.88 | ALDH1A1 (0.47) | ALDH1A1GNAI3GNAO1GNAI1SLC18A3 | |
| SCHEMBL15217761 | 0.88 | GNAI3 (0.43) | ALDH1A1GNAI3GNAO1GNAI1SLC18A3 | |
| SCHEMBL2735017 | 0.87 | GNAI3 (0.50) | ALDH1A1GNAI3GNAO1GNAI1NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023097233-A1 | SPIROCYCLIC CYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| EP-4180432-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2023-05-17 | — | — | EP | disclosed |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-12-22 | — | — | US | disclosed |
| US-20220402948-A1 | EGFR INHIBITOR, COMPOSITION AND PREPARATION METHOD THEREFOR | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2022-12-22 | — | — | US | disclosed |
| WO-2019178510-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2019-09-19 | — | — | WO | disclosed |
| WO-2018067615-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. (US) | 2018-04-12 | — | — | WO | disclosed |
| EP-1960327-B1 | OLIGOMERISATION | THE QUEEN'S UNIV OF BELFAST (GB) | 2017-03-08 | — | — | EP | disclosed |
| EP-2206714-B1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | KYOWA HAKKO KIRIN CO LTD (JP) | 2015-01-21 | — | — | EP | disclosed |
| US-8729264-B2 | Agent for prevention and/or treatment of skin diseases | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-05-20 | — | — | US | disclosed |
| US-8729264-B2 | Agent for prevention and/or treatment of skin diseases | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-05-20 | — | — | US | disclosed |
| US-20100256134-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256134-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20090253680-A1 | SELECTED CGRP-ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20070155790-A1 | Meta-benzamidine derivatives as serine protease inhibitors | LIEBESCHUETZ JOHN W | 2007-07-05 | — | — | US | disclosed |
| US-7223763-B2 | Substituted sulfonamides and ureas useful for inhibiting kinase activity | AVENTIS PHARMACEUTICALS INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223763-B2 | Substituted sulfonamides and ureas useful for inhibiting kinase activity | AVENTIS PHARMACEUTICALS INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7220781-B2 | Meta-benzamidine derivatives as serine protease inhibitors | TULARIK LIMITED (GB) | 2007-05-22 | — | — | US | disclosed |
| WO-2007036532-A2 | SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-04-05 | — | — | WO | disclosed |
| CN-1561212-A | Benzimidazolone Derivatives as Muscarinic Agents | ACADIA PHARM INC (US) | 2005-01-05 | — | — | CN | disclosed |
| US-6743777-B1 | TRISPHENYL ACYL DERIVATIVES OF THE ECHINOCANDIN CLASS; CANDIDA ALBICANS; ANTIFUNGAL AND ANTIPARASITIC; CYCLIC HEXAPEPTIDES HAVING UNIQUE SIDE CHAIN ACYL GROUP | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253680-A1 | SELECTED CGRP-ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | CALCRL, CALCR, BDKRB2 | ALDH1A1 1720/4885GNAI3 442/4885GNAO1 236/4885 |
| US-20070155790-A1 | Meta-benzamidine derivatives as serine protease inhibitors | PEPD, SERPINE1, HPN | ALDH1A1 4419/4885GNAI3 4431/4885GNAO1 3827/4885 |
| US-20220402948-A1 | EGFR INHIBITOR, COMPOSITION AND PREPARATION METHOD THEREFOR | EGFR, ERBB2, ERBB3 | ALDH1A1 3309/4885GNAI3 1234/4885GNAO1 3113/4885 |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | ALDH1A1 4834/4885GNAI3 1094/4885GNAO1 2266/4885 |
| US-20100256134-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | TYR, CUTA, SERPINB1 | ALDH1A1 243/4885GNAI3 2408/4885GNAO1 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.